Drug Trial Radar · NCT05869903
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
3,127
Actual
Start
Jun 5, 2023
Primary completion
Jul 25, 2025
Study completion Oct 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- May 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities. The study has two phases: a main phase and an extension phase. The main phase of the study lasted 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.
Conditions
- Obesity
- Overweight
- Overweight or Obesity
Interventions
OrforglipronDrug
Administered orally.
PlaceboDrug
Administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Body Weight (Primary Treatment Period)Time frame: Baseline, Week 72
Locations
138 sites in 10 countries. Site status is shown where the registry gives one.
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
Chandler, Arizona
Clinical Research Institute of Arizona (CRI) - Sun City West
Sun City West, Arizona
John Muir Physician Network Research Center
Concord, California
AMCR Institute
Escondido, California
NorCal Medical Research, Inc
Greenbrae, California
Velocity Clinical Research, Huntington Park
Huntington Park, California
Velocity Clinical Research, Westlake
Los Angeles, California
Catalina Research Institute, LLC
Montclair, California
Norcal Endocrinology & Internal Medicine
San Ramon, California
University Clinical Investigators, Inc.
Tustin, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
New Age Medical Research Corporation
Miami, Florida
South Broward Research
Miramar, Florida
Renstar Medical Research
Ocala, Florida
Jedidiah Clinical Research - Tampa - Bay Plaza
Tampa, Florida
Clinical Site Partners, LLC dba Flourish Research
Winter Park, Florida
Physicians Research Associates
Lawrenceville, Georgia
East Coast Institute for Research, LLC
Macon, Georgia
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia
East-West Medical Research Institute
Honolulu, Hawaii
Elite Clinical Trials
Blackfoot, Idaho
Cotton O'Neil Clinical Research Center
Topeka, Kansas
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas
Pennington Biomedical Research Center
Baton Rouge, Louisiana
Care Access - Lake Charles
Lake Charles, Louisiana
MedStar Health Research Institute (MedStar Physician Based Research Network)
Hyattsville, Maryland
Endocrine and Metabolic Consultants
Rockville, Maryland
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan
SKY Integrative Medical Center/SKYCRNG
Ridgeland, Mississippi
Las Vegas Medical Research
Las Vegas, Nevada
Long Island Cardiovascular Consultants
Lake Success, New York
Weill Cornell Medical College
New York, New York
Alliance for Multispecialty Research, LLC
Norman, Oklahoma
Texas Diabetes & Endocrinology, P.A.
Austin, Texas
Thyroid, Endocrinology, and Diabetes
Dallas, Texas
Velocity Clinical Research, Dallas
Dallas, Texas
Cedar Health Research
Dallas, Texas
Juno Research
Houston, Texas
Consano Clinical Research, LLC
Shavano Park, Texas
Soma Clinical Trials
Wylie, Texas
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.